Eli Lilly (LLY) Price Target Increased to $1,400, Analysts See 25% Upside
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowOn September 15, Berenberg upgraded Eli Lilly and Company (NYSE: LLY) from Hold to Buy, raising its price target from $1,220 to $1,400. Analysts predict about 25% upside, citing strong investment returns and growth in obesity treatments. Eli Lilly's recent investments total around $60 billion, with more than 25 business development deals made this year. The company faces risks, including US drug pricing reforms and potential competition that may impact growth. This matters to investors as higher price targets suggest analysts expect the stock to perform well.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Eli Lilly and Company (LLY)
Eli Lilly is a major pharmaceutical company known for diabetes and obesity treatments and a broad drug pipeline.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier LLY news
- AbbVie (ABBV) vs. Eli Lilly (LLY): Insights for 2026 Investors
- Eli Lilly (LLY) Receives UK Approval for Orforglipron Weight Diabetes Drug
- Eli Lilly (LLY) Raises Price Target After Positive Quarter Results
- Lilly's Mounjaro and Zepbound Sales Surge Over Novo Nordisk
- S&P 500 Reaches New Highs; Arista (ANET) and Eli Lilly (LLY) Surges
Understand this kind of story
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
